Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02617966 · ClinicalTrials.gov registry record
Rod and Cone Mediated Function in Retinal Disease
A clinical trial of Retinitis Pigmentosa and Retinal Degeneration, sponsored by National Eye Institute (NEI).
- Recruiting
- Registry status
- 500
- Enrollment target
- 1
- Study location
NCT02617966 is a study of Retinitis Pigmentosa and Retinal Degeneration that is actively recruiting participants, run by National Eye Institute (NEI). The registered enrollment target is 500 participants, above the 248-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (102% higher). The trial reports 1 study location across 1 state.
The verdict
NCT02617966, a study of Retinitis Pigmentosa and Retinal Degeneration, is actively recruiting participants, sponsored by National Eye Institute (NEI).
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: Retinal diseases cause the loss of rod and cone photoreceptors. Symptoms include vision loss and night blindness. Researchers want to learn about rod and cone function in healthy people and people with retinal disease. They want to know if how well a person sees in the dark can test the severity of retinal disease. Objectives: To find out if how well a person sees in the dark can test the severity of retinal disease. To find out if this can help detect retinal disease and track its changes. Eligibility: People ages 5 and older with: Retinal disease OR 20/20 vision or better with or without correction in at least one eye Design: Participants will be screened with medical and eye history and eye exam. Those with retinal disease will also have: Eye imaging: Drops dilate the eye and pictures are taken of it. Visual field testing: Participants look into a bowl and press a button when they see light. Electroretinogram (ERG): An electrode is taped to the forehead. Participants sit in the dark with their eyes patched for 30 minutes. Then they get numbing drops and contact lenses. Participants watch lights while retina signals are recorded. Visit 1 will be 3-8 hours. Participants will have up to 6 more visits over 6-12 months. Visits include: Eye exam and imaging Time course of dark adaptation: Participants view a background light for 5 minutes then push a button when they see colored light. Dark adapted sensitivity: Participants sit in the dark for 45 minutes. They push a button when they see colored light. For participants with retinal disease, ERG and visual field testing
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2016-03-24 |
| Est. Completion | 2029-12-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02617966
The ClinicalTrials.gov registry entry for NCT02617966 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 248-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (102% higher). The listed sponsor is National Eye Institute (NEI), which has 221 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Retinitis Pigmentosa appearing as the primary indexed condition, and to 0 interventions.
NCT02617966 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT02617966 about?
NCT02617966 is a clinical study titled "Rod and Cone Mediated Function in Retinal Disease". Background: Retinal diseases cause the loss of rod and cone photoreceptors. Symptoms include vision loss and night blindness. Researchers want to learn about rod and cone function in healthy people and people with retinal disease. They want to know if how well a person sees in the dark can test the...
What is the current status of trial NCT02617966?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2016-03-24. Estimated completion is 2029-12-30.
What conditions does trial NCT02617966 study?
This clinical trial studies the following conditions: Retinitis Pigmentosa, Retinal Degeneration, Stargardt's Disease.
Who is sponsoring clinical trial NCT02617966?
This trial is sponsored by National Eye Institute (NEI), which has 221 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02617966 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retinitis Pigmentosa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Promising ROd-cone DYstrophy Gene therapY
RECRUITING · Phase 1
-
High Resolution Retinal Imaging
RECRUITING
-
Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)
RECRUITING · Phase 2
-
Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration
RECRUITING
-
Retinal Imaging in Patients With Inherited Retinal Degenerations
RECRUITING
-
Cell Collection to Study Eye Diseases
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.